Editas Medicine (EDIT) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Editas Medicine (EDIT) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 32.2% versus a loss of 67.3%. Editas Medicine is the larger company by market cap ($253.1 million vs $245.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | LXEO |
|---|---|---|
| Share price | $1.64 | $2.96 |
| Market cap | $253.12M | $245.05M |
| 1-day change | -4.09% | +0.34% |
| YTD return | -20.00% | -70.19% |
| 1-year return | -32.23% | -67.33% |
| 5-year return | -94.93% | — |
| EPS (TTM) | $-0.54 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | — |
| Revenue growth (YoY) | +25.39% | — |
| Net income (latest FY) | $-160.06M | $-100.00M |
| Operating margin | -394.89% | — |
| Net margin | -395.01% | — |
| 52-week high | $3.94 | $10.99 |
| 52-week low | $1.63 | $2.55 |
| Distance from 52-week high | -58.38% | -73.07% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +271.95% | +748.31% |
| Average volume | 2.63M | 1.98M |
| Shares outstanding | 154.34M | 82.79M |
| Employees | 87 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDIT has outperformed LXEO by 35.1 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
EDIT vs LXEO FAQ
Which is bigger, Editas Medicine or Lexeo Therapeutics?
Editas Medicine (EDIT) is larger, with a market capitalization of $253.12M compared with $245.05M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, EDIT or LXEO?
EDIT returned -32.23% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.